The Outcomes Research Program has the following four specific aims: 1) Evaluate the outcomes of cancer, including health-related quality of life, in a broad range of health care settings 2) Assess the effectiveness and costs of new &established interventions to prevent, detect and treat cancer 3) Identity determinants of the quality of cancer care 4) Characterize barriers to optimal care with a special focus on racial, ethnic and socioeconomic disparities in cancer care and approaches to eliminate disparities in care To achieve these objectives, the Program has assembled a multi-disciplinary group of investigators with demonstrated expertise in the methods of health services research and a proven commitment to the study of cancer outcomes. Their research spans the continuum from basic methodological studies, through clinical applications, to policy applications. The Program was originally funded in 2000 when Dana-Farber/Harvard Cancer Center was established, and it was rated as "outstanding" in the last renewal in 2005. The Program is led by J. Ayanian(BWH) and J.Weeks(DFCI) and currently has 54 members from 11 HMS departments and three HSPH departments with representation from all seven member institutions. In 2009, Program members were awarded $14.2 million in research funding (total costs), which includes over $9 million in NCI funding and $2.8 million in other federal peer-reviewed funding. The total number of publications from members of the Program during the project period (2006 to 2010) was 1,055. Ofthese 17% ofthese were intra-programmatic collaborations, 33% were inter-programmatic, and 24% were inter-institutional.
The Outcomes Research Program focuses on enhancing the effectiveness and cost-effectiveness of interventions to prevent, diagnose and treat cancer and its consequences. The primary focus is on evaluating interventions that optimize patient-oriented outcomes, identifying barriers to optimal care of all patients, defining approaches to eliminate these barriers, and ensuring that society's resources are allocated effectively to achieve those goals.
|Hu, Yanhui; Comjean, Aram; Roesel, Charles et al. (2016) FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2017 update. Nucleic Acids Res :|
|Hong, Theodore S; Wo, Jennifer Y; Yeap, Beow Y et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34:460-8|
|Freedman, Rachel A; Gelman, Rebecca S; Wefel, Jeffrey S et al. (2016) Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34:945-52|
|Mohr, Stephanie E; Hu, Yanhui; Ewen-Campen, Benjamin et al. (2016) CRISPR guide RNA design for research applications. FEBS J 283:3232-8|
|Brunner, Andrew M; Li, Shuli; Fathi, Amir T et al. (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175:496-504|
|Cox, Andrew G; Hwang, Katie L; Brown, Kristin K et al. (2016) Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol 18:886-96|
|McKay, Tina B; Hjortdal, Jesper; Sejersen, Henrik et al. (2016) Endocrine and Metabolic Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal Microenvironment. Sci Rep 6:25534|
|Nelms, Bradlee D; Waldron, Levi; Barrera, Luis A et al. (2016) CellMapper: rapid and accurate inference of gene expression in difficult-to-isolate cell types. Genome Biol 17:201|
|Tan, Justin L; Fogley, Rachel D; Flynn, Ryan A et al. (2016) Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell 62:34-46|
|Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381|
Showing the most recent 10 out of 303 publications